Why the study?
Reports are conflicting regarding the efficacy of mTOR inhibitors in treating established CAV, and most prior data relied on short-term follow-up.
Do mTOR inhibitors reduce the development and progression of cardiac allograft vasculopathy in heart transplant recipients?
Do mTOR inhibitors reduce the development and progression of cardiac allograft vasculopathy in heart transplant recipients?
This review highlights that early initiation of mTOR inhibitors post-heart transplant may prevent CAV, though their role in established disease requires further clarification.
May support early mTOR inhibitor use to limit CAV development post-transplant; leaves open efficacy in established disease pending RCTs.
Cardiac allograft vasculopathy (CAV) is a progressive fibroproliferative disease, which contributes to significant morbidity and mortality during long-term follow-up after heart transplantation. Mammalian target of rapamycin (mTOR) inhibitors have favorable effects on endothelial function and reduce intimal proliferation, and their early use after transplantation has been associated with a reduction in the risk of development and progression of CAV. However, there are conflicting reports on the efficacy of these agents in treating established CAV. Most of the data until recently have been based on short-term follow-up, and CAV was assessed by changes in intravascular ultrasound. In this study, we review the mechanism of action of mTOR inhibitors and their protective role in CAV and summarize some of the recent literature, which include long-term follow-up using this class of medications.
No takes yet. Share an insight, caveat, or question.
Bellumkonda et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: